Back to top
more

Heska Corporation (HSKA)

(Delayed Data from NSDQ)

$79.28 USD

79.28
71,295

+3.36 (4.43%)

Updated May 3, 2019 04:00 PM ET

After-Market: $79.10 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Biogen to License Alzheimer Candidate from Bristol-Myers

Biogen Inc. (BIIB) recently announced that it has inked a deal to buy worldwide rights for Bristol-Myers Squibb's (BMY) anti-tau antibody, BMS-986168, for an upfront payment of $300 million.

    MiMedx Group (MDXG) Catches Eye: Stock Jumps 8.5% in Session

    MiMedx Group, Inc. (MDXG) moved big last session, as its shares rose above 8% on the day.

      Neurocrine's Stock Up, FDA Nod for Tardive Dyskinesia Drug

      Shares of Neurocrine Biosciences, Inc. (NBIX) soared 25% on Tuesday after announcing the FDA approval ofIngrezza (valbenazine) capsules a day before for the treatment of adults with tardive dyskinesia (TD).

        Roche Launches Antibody Test to Diagnose Prostate Cancer

        Roche Holding AG (RHHBY) announced that it has launched the anti-p504s (SP116) Rabbit Monoclonal Primary Antibody for prostate cancer diagnosis on a world wise basis.

          Illumina (ILMN) Launches VeriSeq NIPT Solution in Europe

          Illumina, Inc. (ILMN) recently announced the launch of a solution pertaining to its noninvasive prenatal testing (NIPT) range in Europe.

            Bristol-Myers (BMY) Collaborates with Apexigen for Opdivo

            Bristol-Myers Squibb Company (BMY) announced a collaboration agreement with clinical-stage biopharmaceutical company Apexigen, Inc.

              Pacira Focuses on Lead Candidate Exparel's Label Expansion

              We issued an updated report on Pacira Pharmaceuticals, Inc. (PCRX) on Apr 11.

                Ohr Pharmaceutical Provides Update on Squalamine Study

                Ohr Pharmaceutical, Inc. (OHRP), announced it plans to amend the ongoing MAKO Study evaluating Squalamine (also known as OHR-102) in wet form of age-related macular degeneration (wet-AMD).

                  OncoMed Cancer Candidate Fails Trial, Bayer Opts Out of Deal

                  It was a bad day for OncoMed Pharmaceuticals, Inc. (OMED) as it suffered two setbacks.

                    Endo (ENDP) Reports Preliminary Results for First Quarter

                    Endo International plc (ENDP) recently announced preliminary results for first-quarter 2017.

                      ANTH's (ANTH) Blisibimod Completes Dosing in Phase III Study

                      Anthera Pharmaceuticals, Inc. (ANTH) recently announced the completion of dosing in a phase II study, BRIGHT-SC. The study evaluated key pipeline candidate blisibimod for treatment of patients with IgA nephropathy (IgAN).

                        Gilead (GILD) HCV Drugs Gets FDA Nod for Label Expansion

                        Gilead Sciences, Inc. (GILD) announced that the FDA approved additional indications for Harvoni tablets and Sovaldi tablets.

                          Roche's Lung Cancer Drug Alecensa Meets Primary Endpoint

                          Roche (RHHBY) announced that the global, randomized phase III study, ALEX, on lung cancer drug Alecensa met its primary endpoint as an initial (first-line) treatment.

                            Ultragenyx's (RARE) XLH Drug Positive in Phase II Study

                            Ultragenyx Pharmaceutical Inc. (RARE) and its Japanese partner Kyowa Kirin International plc recently announced positive 64-week data from a pediatric phase II study, evaluating its investigational candidate burosumab (KRN23).

                              Regeneron's Evinacumab Gets Breakthrough Therapy by FDA

                              Regeneron Pharmaceuticals, Inc. (REGN) announced that the FDA has granted Breakthrough Therapy Designation status to ievinacumab for the treatment patients with Homozygous Familial Hypercholesterolemia.

                                Bristol-Myers' (BMY) sBLA For Opdivo Accepted by the FDA

                                Bristol-Myers Squibb Company (BMY) recently announced that the FDA has accepted the company's supplemental Biologics License Application (sBLA) for the label expansion of immune-oncology drug Opdivo.

                                  David Bartosiak headshot

                                  Today's Strong Buy Stocks at New Highs

                                  Wild day in the markets and four strong buys at new highs

                                    Celgene (CELG) Gets Paragraph IV Notice Letter for Pomalyst

                                    Celgene Corporation (CELG) recently received a Paragraph IV Notice Letter advising that Teva Pharmaceutical Industries Limited (TEVA) submitted an ANDA to the FDA seeking an approval to manufacture and market a generic version of Pomalyst.

                                      Roche Announces Positive Data on Lung Cancer Drug Alecensa

                                      Roche Holdings AG (RHHBY) recently announced encouraging results from the phase III study, ALUR on lung cancer drug Alecensa.

                                        Valeant (VRX) Faces Pricing Issues, Generic Threats Loom

                                        Shares of Valeant Pharmaceuticals International, Inc. (VRX) hit a 52-week low of $10.08 on Apr 4.

                                          Agenus (AGEN) Sharpens Focus on Drug Development Programs

                                          We issued an updated report on Agenus Inc. (AGEN) on Apr 4.

                                            Amedisys (AMED) Poised on Strong Home Health, Risks Remain

                                            On Apr 04, we issued an updated research report on renowned home health and hospice services provider, Amedisys Inc. (AMED).

                                              Galapagos Initiates 3 Phase II Studies for Filgotinib

                                              Galapagos NV (GLPG) announced that it has initiated three new phase II Proof-of-Concept studies evaluating its pipeline candidate filgotinib in Sjogren's syndrome, ankylosing spondylitis (AS), and psoriatic arthritis.

                                                Bristol-Myers Announces Data on Immuno-oncology Drug Opdivo

                                                Bristol-Myers Squibb Company (BMY) recently announced encouraging data from various trials on Opdivo.

                                                  QIAGEN Releases Favorable GeneReader Results, Expands in NGS

                                                  QIAGEN N.V. (QGEN) recently has validated its GeneReader NGS System and published five new independent studies.